Edina, Michigan Clinical Trials

A listing of Edina, Michigan clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 58 clinical trials
Caterpillar Arterial Embolization Device Post-Market Study

The primary objective of this study is to evaluate the performance and safety of the Caterpillar Arterial Embolization Device when used for arterial embolization in the peripheral vasculature in a real world, on-label application.

University of Minnesota Medical Center - Fairview
 (8.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +11 other locations
A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease

This is a non-randomized, open-label, multi-site, single-dose, Phase 3 study in approximately 35 adults and pediatric subjects 2 and 50 years of age with sickle cell disease (SCD). The study will evaluate hematopoietic stem cell (HSC) transplantation (HSCT) with LentiGlobin BB305 Drug Product for SCD.

priapism
pediatric
gene therapy
karnofsky performance status
analgesia
University of Minnesota
 (8.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

Primary Objectives: To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function To assess the safety and tolerability of lademirsen (SAR339375) in subjects with Alport syndrome Secondary Objectives: To assess plasma pharmacokinetic (PK) parameters of the parent compound and its metabolites To assess the potential formation …

University of Minnesota Childrens' Hospital_Investigational Site Number :8400003
 (7.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +22 other locations
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome  

Primary Objectives: To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function To assess the safety and tolerability of lademirsen (SAR339375) in subjects with Alport syndrome Secondary Objectives: To assess plasma pharmacokinetic (PK) parameters of the parent compound and its metabolites To assess the potential formation …

University of Minnesota Childrens' Hospital_Investigational Site Number :8400003
 (7.5 away)
  • 0 views
  • 01 Dec, 2025
  • +19 other locations
None

HealthPartners Institute
 (3.9 away) Contact site
  • 0 views
  • 19 May, 2025
  • +19 other locations
A Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease (RESULT)

This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or primary minimal change disease (MCD).The purpose of this study is to measure the change in proteinuria and its impact on the rates of remission of nephrotic syndrome with frexalimab, SAR442970, or …

Investigational Site Number : 8400019
 (1.4 away) Contact site
  • 0 views
  • 20 Jun, 2025
  • +24 other locations
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer ALCHEMIST Chemo-IO Study

This phase III ALCHEMIST trial compares the addition of pembrolizumab to usual chemotherapy versus usual chemotherapy for the treatment of stage IB, II, or IIIA non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the …

absolute neutrophil count
squamous non-small cell lung cancer
stage iia lung squamous cell carcinoma ajcc v7
squamous non-small cell lung carcinoma
EGFR
Fairview Southdale Hospital
 (1.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +358 other locations
Test CPR 2  

Test CPR 2

Site with Site User
 (8.8 away)
  • 0 views
  • 19 Feb, 2024
  • +2 other locations
None

HealthPartners Institute
 (3.9 away) Contact site
  • 0 views
  • 19 May, 2025
  • +12 other locations
None

HealthPartners Institute
 (3.9 away) Contact site
  • 0 views
  • 19 May, 2025
  • +13 other locations